iOmx Therapeutics raises EUR65m in Series B round
Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, has closed a Series B round totalling EUR65 million. The financing was co-led by Athos Service GmbH – the Strüngmann family office – and MIG Capital AG, with participation from existing investors Wellington Partners,